Randomized Clinical Trial of the Effect of a Fibrin Sealant Patch on Pancreatic Fistula Formation After Pancreatoduodenectomy
Overview
Authors
Affiliations
Background: The potential for a fibrin sealant patch to reduce the risk of postoperative pancreatic fistula (POPF) remains uncertain. The aim of this study was to evaluate whether a fibrin sealant patch is able to reduce POPF in patients undergoing pancreatoduodenectomy with pancreatojejunostomy.
Methods: In this multicentre trial, patients undergoing pancreatoduodenectomy were randomized to receive either a fibrin patch (patch group) or no patch (control group), and stratified by gland texture, pancreatic duct size and neoadjuvant treatment. The primary endpoint was POPF. Secondary endpoints included complications, drain-related factors and duration of hospital stay. Risk factors for POPF were identified by logistic regression analysis.
Results: A total of 142 patients were enrolled. Forty-five of 71 patients (63 per cent) in the patch group and 40 of 71 (56 per cent) in the control group developed biochemical leakage or POPF (P = 0·392). Fistulas were classified as grade B or C in 16 (23 per cent) and ten (14 per cent) patients respectively (P = 0·277). There were no differences in postoperative complications (54 patients in patch group and 50 in control group; P = 0·839), drain amylase concentration (P = 0·494), time until drain removal (mean(s.d.) 11·6(1·0) versus 13·3(1·3) days; P = 0·613), fistula closure (17·6(2·2) versus 16·5(2·1) days; P = 0·740) and duration of hospital stay (22·1(2·2) versus 18·2(0·9) days; P = 0·810) between the two groups. Multivariable logistic regression analysis confirmed that obesity (odds ratio (OR) 5·28, 95 per cent c.i. 1·20 to 23·18; P = 0·027), soft gland texture (OR 9·86, 3·41 to 28·54; P < 0·001) and a small duct (OR 5·50, 1·84 to 16·44; P = 0·002) were significant risk factors for POPF. A patch did not reduce the incidence of POPF in patients at higher risk.
Conclusion: The use of a fibrin sealant patch did not reduce the occurrence of POPF and complications after pancreatoduodenectomy with pancreatojejunostomy. Registration number: 2013-000639-29 (EudraCT register).
Health and Economic Advantages Associated With the Use of TachoSil: An Update of Systematic Review.
Colombo G, Droghetti A, Di Matteo S, Ottenjann H, Bruno G Ther Clin Risk Manag. 2025; 21:257-271.
PMID: 40046260 PMC: 11881641. DOI: 10.2147/TCRM.S476650.
Xue K, Wang L, Chen L, Liu X, Li A, Wang Z Gland Surg. 2024; 13(10):1693-1707.
PMID: 39544981 PMC: 11558298. DOI: 10.21037/gs-24-235.
Stent A pancreaticojejunostomy after pancreatoduodenectomy: Is it always necessary?.
Symeonidis D, Zacharoulis D, Tzovaras G, Kissa L, Samara A, Petsa E World J Methodol. 2024; 14(3):90164.
PMID: 39310242 PMC: 11230077. DOI: 10.5662/wjm.v14.i3.90164.
Walber J, Antony P, Strothmann H, Kalkum E, Renzulli P, Hauswirth F BJS Open. 2024; 8(3).
PMID: 38814751 PMC: 11138960. DOI: 10.1093/bjsopen/zrae059.
Surgical management of pancreatic ductal adenocarcinoma: a narrative review.
Sarfaty E, Khajoueinejad N, Zewde M, Yu A, Cohen N Transl Gastroenterol Hepatol. 2023; 8:39.
PMID: 38021357 PMC: 10643215. DOI: 10.21037/tgh-23-27.